MPR Weekly Dose

First chikungunya vaccine approved; FDA send warning letter to Amazon about ophthalmic products; at-home STD test cleared; Bayer withdraw lymphoma drug; and a combo treatment to reduce catheter-related bloodstream infections is approved.

New weight management approved; Novo Nordisk discontinue Levemir; adjunctive system for hypertension patients; frontotemporal dementia treatment given Fast Track designation; and the FDA advise against use of glucose supplement.

FDA urge immediate discontinuation for eye drop products; safety alert issued for the pediatric Moderna COVID-19 vaccine; novel heartburn medicine approved; Stelara biosimilar approved; and an antibody to prevent fentanyl overdose gets fast tracked.

New pentavalent meningococcal vaccine approved; Gohibic's shelf-life extended by 6 months; maintenance treatment approved for adults with moderately to severely active ulcerative colitis or Crohn disease; self-administered option for FluMist Quadrivalent accepted for review; intravenous combo formulation of acetaminophen and ibuprofen approved for postoperative pain.

FDA approves a novel treatment for major depressive disorder; vote taken on stem cell therapy for ALS; preservation-free Iyuzeh now available; CDC recommends RSV vaccine for during pregnancy; investigational treatment shows promise in familial chylomicronemia syndrome.

Bacterial pneumonia treatment now available; FDA deny proposed anaphylaxis treatment; Results on flu vaccine efficacy; More flexible dosing for Talicia; Change in the therapeutic equivalence for organ rejection drug generic. 

The FDA and CDC greenlight updated COVID-19; prescription drug for dry eye disease now available; head-to-head study comparing Skyrizi to Stelara for Crohn disease; the REMS program has been updated for IBS treatment Lotronex; and the FDA cracks down on companies selling unnaproved eye products.

With fall on the horizon, MPR sat down with Assistant Professor of Clinical Pharmacy at the University of California San Diego, Dr. Abdul-Mutakabbir. Our wide ranging talk covers the updated COVID-19, flu and RSV vaccines. We also discuss vaccine hesitancy, health equity and representation in medicine.

New vaccine guidelines issued for the 2023-2024 flu season; USPSTF make recommendations on PrEP prescribing; maternal RSV vaccine; updated COVID vaccine shows strong immune response; new treatment approved for rare immune disease.

FDA issue recommendations to avoid Company's tests; RSV vaccine now available for older adults; New treatments approved for fibrodysplasia ossificans progressiva and for those with metastatic uveal melanoma with unresectable hepatic metastases; and gastrointestinal associations issue a statement regarding GLP-1 use prior to upper gastrointestinal endoscopy.

Oral postpartum depression treatment approved; generic naloxone nasal spray now available; weight management drug shows promise in reducing major cardiovascular events; CDC recommends routine use of RSV vaccine; social anxiety disorder spray shows potential.

Drug agencies issue letter addressing the prescription stimulant shortage; electronic transfer of controlled substances given green light; oral contraceptives recalled; expanded indication for Ebola vaccine; and a new over-the-counter opioid overdose treatment.

Single-use application to treat the molluscum contagiosum approved; Xdermvy has gotten the green light to treat demodex blepharitis; warfarin reversal treatment for use in urgent surgery; weight loss drug in short supply through 2023; cervical pessary assessed for reducing preterm birth.

Study supports the benefit of potential new Alzheimer drug; RSV treatment approved for neonates and infants; Veklury approval expanded; a blood test used to diagnose life-threatening heart muscle injuries has been recalled; Brenzavvy available for adults.

First over-the-counter birth control pill; expanded approval for Leqvio; Gavreto has an indication withdrawn; batches of Albuterol inhalers recalled; results from analysis of paclitaxel-coated devices.

New approvals for alopecia, generalized myasthenia gravis and type 1 diabetes; New colonoscopy prep option; And FDA denies application for pre-chirrotic fibrosis due to NASH.

FDA revoke Emergency Use Authorization for a COVID-19 vaccine; New approval for treatment of iron deficiency in patients with heart failure; Lumryz now available for excessive daytime sleepiness; Vowst approved for C. difficile infection; Prevymis approved for prophylaxis of CMV disease in adult kidney transplant recipients.

New vaccine for lower respiratory tract disease; A new treatment for heart failure; Concerns over some compounded semaglutide; New opioid use disorder treatment; Motion sickness Tx shows promise.  

First oral antiviral approved for COVID-19; First topical treatment approved for epidermolysis bullosa; Xacduro gets green like for bacterial pneumonia; New nasal spray for opioid overdoses; Child cough suppressant recalled.

FDA requires label updates for the entire class of prescription stimulants; Novel treatment approved for menopause symptoms; FDA Committee takes votes on potentially accelerated approval of Duchenne muscular dystrophy gene therapy; Fungal meningitis outbreak in US; Wearable child thermometer recalled.

Panel votes unanimously in favour of over-the-counter change for contraceptive pill; First pharmacological therapy for agitation associated with dementia due to Alzheimer disease; Elfabrio approved for the treatment of Fabry disease; Farxiga approval expanded; Bacterial contamination concerns for certain COVID-19 at-home tests.

Investigational treatment for early Alzheimer disease shows promise; First vaccine for the prevention of lower respiratory tract disease caused by RSV; Nightly granules approved for narcolepsy; Latest health tech advance in toilets; And the FDA warns of energy boosting over-the-counter inhalants.

Large recall of drugs due to company shutdown; First orally administered fecal microbiota treatment given green light; Treatment approved for certain ALS patients; Type 2 diabetes insulin delivery system; FDA issue safety alert concerning eyedrops.

Updates to COVID-19 vaccines; FDA panel votse on potential treatment for agitation with Alzheimer dementia; DEA deschedule drug; Migraine treatment indication expanded; A new device is cleared to aid in restless legs syndrome.

Implantable device approved for those with knee osteoarthritis; Prescribing Information labeling updated for opioids; Imbruvica indications withdrawn; Patch to combat excessive underarm sweating given green light; Novel treatment Fast Tracked for Type A and B influenza.